CliffBio
small molecule

CYPSEDO

CIPEPOFOL

Loss of exclusivityAugust 2031FDA regulatory exclusivity expiry
CompanyHAISCO-USA PHARMACEUTICALS INC

Drug detail

Brand nameCYPSEDO
Active ingredientCIPEPOFOL
Strength50MG/20ML (2.5MG/ML)
Dosage formEMULSION
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalAugust 2026
Marketing statusRX

Regulatory exclusivity

CodeExpires
NCEAugust 2031

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the FDA regulatory exclusivity expiry; estimates are projections, not legal advice.